The COVID 19 pandemic didn’t seriously impede the construction and cargo of prescribed drugs in the 1st quarter of 2020, although the months ahead will be important as chemical deliveries decelerate and inventories of backup provides dwindle. What the pandemic has done is get up regulators and world leaders to the extent to which China dominates the area’s supply of active pharmaceutical additives and their chemical raw materials. An ongoing industry effort in the US and Europe to rebalance the pharmaceutical chemical supply chain is probably going to be energized by executive tasks to ensure domestic production of substances. Janet Woodcock, director of the US Food and Drug Administration’s Center for Drug Evaluation and Research, told a House of Representatives subcommittee on health in October that the number of facilities in China providing active pharmaceutical ingredients APIs had greater than doubled since 2010 to 13% of all those serving the US market. In December, a delegation of the European Fine Chemicals Group EFCG, an affiliation representing API brands, knowledgeable EC commissioners about measures needed to help the repatriation of pharmaceutical chemical construction from China back to Europe.
Giuliano Perfetti, director of sales, marketing, and business development at Fabbrica Italiana Sintetici, an Italian CDMO, headed a task force that constructed the doc the EFCG offered in Brussels. It requires fast track popularity of trade providers of regulated drug starting ingredients and the institution of a Europe wide database, just like the FDA’s, on supply chain issues comparable to shortages of key ingredients. It also seeks a 5 to 10 year investment plan to help the advancement of clean, or green, chemistry technologies to help reestablish production of basic pharmaceutical chemical compounds in Europe.